Northwest Biotherapeutics (NWBO) Other Non-Current Liabilities (2014 - 2026)

Northwest Biotherapeutics' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $38.7 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 17.91% year-over-year to $38.7 million in Q1 2026; TTM through Mar 2026 was $38.7 million, a 17.91% decrease from a year earlier, with the FY2025 full-year figure at $47.1 million, up 1.95% from the prior year.
• Other Non-Current Liabilities fell to $38.7 million in Q1 2026 per NWBO's latest filing, from $47.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $107.9 million in Q1 2022 and bottomed at $10.0 million in Q2 2023.
• The 5-year median for Other Non-Current Liabilities is $46.2 million (2024), against an average of $46.6 million.
• Across the five-year window, Other Non-Current Liabilities plunged 90.29% in 2023 and soared 154.95% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $90.7 million in 2022, then slumped by 74.22% to $23.4 million in 2023, then soared by 97.4% to $46.2 million in 2024, then advanced by 1.95% to $47.1 million in 2025, then declined by 17.75% to $38.7 million in 2026.
• Per Business Quant, the three latest NWBO Other Non-Current Liabilities figures stand at $38.7 million (Q1 2026), $47.1 million (Q4 2025), and $60.8 million (Q3 2025).